



(51) International Patent Classification:

A61Q 19/00 (2006.01) A61K 8/97 (2006.01)  
A61K 8/34 (2006.01) A61K 36/76 (2006.01)  
A61K 8/365 (2006.01) A61K 8/60 (2006.01)

(21) International Application Number:

PCT/EP2016/000312

(22) International Filing Date:

23 February 2016 (23.02.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

EP15000576 27 February 2015 (27.02.2015) EP

(71) Applicant: **ROTTAPHARM LTD.** [IE/IE]; Damastown Industrial Park, Mulhuddart, Dublin 15 (IE).

(72) Inventors; and

(71) Applicants (for US only): **GASPARRI, Franco** [IT/IT]; Via Beccara, 12, 40020 Casalfiumanes (BO) (IT). **MANTEGAZZA, Raffaella** [IT/IT]; Via Prina, 8, 20800 Monza (MB) (IT). **BELTRANDI, Martina** [IT/IT]; Via Annoni, 2, 12084 Mondovi (IT). **ZARNARDI, Andrea** [IT/IT]; Via Marcantonio dal Re, 20, 20156 Milano (IT).

(74) Agent: **KÜCH, Angelika**; MEDA PHARMA GMBH & CO KG, Corp. Patent & Trademark Dept., Benzstr. 1, 61352 Bad Homburg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: COMPOSITION FOR THE TREATMENT OF ACNE

(57) Abstract: The present invention describes a cosmetic or dermatological composition for use in the antibacterial and/or anti-inflammatory treatment comprising a combination of vegetal extracts titrated in salicin and 1,2-alkanediols, preferably 1, 2-decanediol and willow bark (*Salix alba*) extract.



WO 2016/134846 A1

## Composition for the treatment of acne

The present invention describes a cosmetic or dermatological composition for use in the treatment of acne comprising a combination of vegetal extracts titrated in salicin and 1,2-alkanediols, preferably 1, 2-decanediol and willow bark (*Salix alba*) extract.

5

Acne vulgaris is the most frequently diagnosed dermatosis in patients in the age between 11 and 30. It is believed that acne affects about 80% of persons in this age group or even, taking into account lesions of low intensity, 100% of young people. The aetiopathogenesis of acne is multifactorial. In all patients with acne, the following symptoms occur: excessive  
10 sebum production, excessive keratosis of excretory ducts and openings of sebaceous glands, development of bacterial flora and release of inflammatory mediators in the skin.

In 95% of the patients, lesions are situated on the face and on the upper parts of the trunk, occasionally on the other parts of the body, and due to this location and the chronic nature of the disease, the patients have serious psychological problems.

15

Excessive sebum production and accumulation and blocked sebaceous gland openings favour bacterial colonization. Microcomedones are inhabited mostly by *Propionibacterium acnes*, a micro-organism mainly involved in the development of acne. Other bacteria are inter alia: *Staphylococcus epidermidis* and *Malassezia furfur*. Due to the presence of lipase, this  
20 microorganism hydrolyses sebum di- and triglycerides to free fatty acids. Free fatty acids, which arise during the hydrolysis process, have the irritating, proinflammatory effect and intensify follicular keratosis. Also hyaluronidase, proteases and neuraminidases, produced by *Propionibacterium acnes*, have the pro-inflammatory effect. Moreover, this microorganism releases low-molecular chemotactic factors (peptides), attracting neutrocytes, and it activates  
25 both the alternative complement pathway and a classic immune response. The activator of the alternative complement pathway is the cell wall of *Propionibacterium* (B. Bergler-Czop, International Journal of Cosmetic Science, 2014, 36, 187–194).

Microorganisms like *Propionibacterium acnes* can prompt the secretion of a variety of  
30 cutaneous anti-microbial peptides (AMPs). The inflammatory effects of *P. acnes* do not require the organism to be alive or be present in its entirety. In vitro, supernatants containing either membranous peptidoglycans (PG) and lipopolysaccharides (LPS) or, cytosolic contents or membrane proteins were able to increase keratinocyte expression of TLR2 and TLR4.

It is well known that further cytokines play a significant role in acne inflammation. *Propionibacterium acnes* triggers the pro-inflammatory mediators through activation of Toll-like receptor 2 (TLR2). Among these mediators is IL-8 the expression of which is induced by *P. acnes*.

- 5 Tumor necrosis factor-alpha (TNF-alpha) is another pro-inflammatory cytokine involved in acne pathogenesis (Archives of Dermatological Research 2008, Volume 300, No 7, pp 371-376).

10 The extract of white willow bark (*Salix alba*) contains salicin and its derivatives, which have been used for longer than a century as antipyretic agents and in the treatment of many rheumatic disorders.

Herbal medicinal products such as various formulations from the bark of *Salix* species are well recognised throughout Europe for treating inflammatory conditions and pains of different origin.

- 15 *Salix* extracts have demonstrated analgesic, antiphlogistic and antipyretic effects in various animal models (Loniewski et al. 2002).

For example, dose-dependent effects have been reported in the hot-plate and carrageenan-induced paw edema tests in rats (established test procedures to demonstrate analgesic and anti-inflammatory effects, respectively) for a *Salix* extract containing 12% salicin (Loniewski  
20 et al. 2002).

Salicin has been known as a potent anti-inflammatory agent when taken orally.

It is believed that salicin may have anti-aging capabilities when applied topically to human skin. The data from a study show that topical application of a serum formulation containing 0.5% salicin offers wide-spectrum anti-aging benefits, targeting the major signs of visible  
25 human skin aging. Statistical improvements were indicated in structure-related signs of skin aging against baseline. These include wrinkles, fine lines, jaw-line contour, firmness, extensibility, and density. Statistical improvements were also seen in mottled pigmentation, uneven skin tone, radiance, hydration and tactile roughness against baseline. These results substantiate salicin's ability to improve the visible signs of aging, when applied topically to  
30 human skin in a product formulation. (Gopaul Remona et al., An evaluation of the effect of a topical product containing salicin on the visible signs of human skin aging Journal of Cosmetic Dermatology, 9, 196–201)

From prior art it has been known that salicin has may be useful as anti-irritative active compound in cosmetic and topical dermatological preparations (EP 0801946).

Salicin is also useful in combinations with additional herbal extracts. DE 10034328 discloses a cosmetic formulation for external application to skin, especially skin reddened by acne rosaceae, containing quercetin, rutin, salicin and escin in aqueous medium.

5 1,2-Alkanediols like 1,2-pentanediol (INCI: Pentylene Glycol), 1,2-hexane diol (INCI: 1,2-Hexanediol) and 1,2-octanediol (INCI: Caprylyl Glycol) as well as combinations thereof are multifunctional ingredients widely used in personal care products as moisturizers and antibacterial agents. It is well known to the person skilled in the art that these substances show specific antibacterial activity against *P. acnes*.

10

WO 201117126 describes a combination of 1,2-decanediol and licochalcone A and carnitine which is effective against *Propionibacterium acnes* (*P. acnes*) without irritating the skin.

EP 1731036 discloses mixtures containing different 1,2-alkanediols for acne treatment.

15 Conventional products for the treatment of oily and blemished skin, eg. aqueous/ethanolic and / or surfactant-containing cleaning products have the disadvantage to strain usually the skin to dry out and work only little skin caring. It is particularly disadvantageous that the body's reaction to the use of ethanol and / or detergents-containing solutions over a longer period of time may be an overproduction of sebum, which counteracts the primary  
20 therapeutic goal of sebum reduction in oily, blemished and acne prone skin.

For the topical treatment of acne there are acne agents, such as strong oxidizing agents, such as. benzoyl peroxide; alpha-hydroxy acids, such as salicylic acid and lactic acid; aliphatic dicarboxylic acids such as azelaic acid; retinoids such as tretinoin (synonym: all-trans-retinoic acid), all-trans-retinal and 13-cis-retinoic acid (isotretinoin); antiandrogens  
25 (5alpha-reductase) and antibiotics such as clindamycin, tetracycline and erythromycin.

Said substances usually have only a very moderate antimicrobial activity against *P. acnes* and have to be used in a relatively high concentration - benzoyl peroxide for example, with up to 5 wt.-%, and azelaic acid with up to 20 wt.-% - in cosmetic and dermatological formulations.

30 Due to the high dosage, however, the skin is extremely disadvantageous heavily overused, which is manifested particularly in very dry skin, which is often associated in part with severe skin irritation due to the strong reduction of the pH of the skin.

The effectiveness of the strong oxidizing agent such as benzoyl peroxide, the alpha hydroxy acids such as salicylic acid and lactic acid, and the aliphatic dicarboxylic acids such as azelaic acid is based on the inhibition of *P. acnes*.

- 5 It is desirable to have a cosmetic or dermatological preparation to provide acne treatment that has an improved activity against *Propionibacterium acnes* (*P. acnes*) and improved inflammatory activity especially against inflamed comedones without severely irritating the skin.

10 The problem is solved by a cosmetic or dermatological composition comprising a combination of 1, 2-decanediol and willow bark extract. This preparation surprisingly shows a synergistic antibacterial and anti-inflammatory effect compared to the single substances.

### **Experimental Part**

#### **Determination of MIC and MBC on Gram positive bacteria**

- 15 Aim of the test

The aim of the test was to determine the antimicrobial activity of one or more samples against a micro-organism. The values obtained must be considered characteristic of the test sample for a determined microbial species under determined test conditions.

#### Description of the method

- 20 A series of test tubes was prepared containing the culture broth inoculated with the test micro-organism and the substance to be tested was introduced at decreasing scalar concentrations.

The cultures were incubated at the optimal temperature and under optimal growth conditions of the preselected micro-organism and for a sufficient period of time to demonstrate  
25 development.

The test tubes in which the microbial population developed were then determined by observing visually the turbidity that is indicative of growth. Test tubes in which the substance is present at a sufficient concentration to inhibit growth remain clear. When the nature itself of the sample prevents visual reading or if it is wished to determine whether the lack of  
30 development is due to a microbiostatic or microbicidal action, transfers are made to appropriate agar media for confirmation.

#### Criteria of interpretation

The concentration of sample at which growth of the micro-organisms is inhibited is considered to be the Minimum Inhibitory Concentration (MIC), while that at which viable micro-organisms are no longer present is considered to be the Minimum Bactericidal Concentration (MBC)

5

A) Evaluation of the antibacterial activity of different substances against *Staphylococcus* species

A test to evaluate antibacterial activity against Gram positive bacteria was conducted evaluating the following substances:

10 Bakuchiol, Lactoferrin, Lauric acid, Resveratrol, *Salix alba* extract.

The antibacterial activity of these substances against *Staphylococcus aureus acnes* ATCC 25923 and *Staphylococcus epidermidis* ATCC 12228 was tested according to the above-described method. The results are shown in Table 1.

15 Table 1

	<i>Staphylococcus aureus</i> ATCC 25923		<i>Staphylococcus epidermidis</i> ATCC 12228	
	MIC (µg/ml)	MBC (µg/ml)	MIC (µg/ml)	MBC (µg/ml)
Bakuchiol	6.25	100	6.25	100
Lactoferrin	>20000	-	>20000	-
Lauric Acid	250	1.000	500	1000
Resveratrol	1000	>100000	250	>100000
<i>Salix alba</i> extract	30000	100000	30000	100000

Minimum Inhibition Concentration (MIC) and Minimum Bactericide Concentration (MBC) of different substances against *Staphylococcus aureus acnes* and *Staphylococcus epidermidis*

20 The test showed poor activity of *Salix alba* extract against Gram positive bacteria with respect to other substances tested.

25

B) Evaluation of the antibacterial activity of different substances against *P. acnes*

In a further set of experiments we tested the antibacterial activity of *Salix alba* extract and 1,2-decanediol, a substance which is known to show antibacterial activity against *P. acnes*, alone and in combination according to the above-described method.

- 5 The microbial strain used was *Propionibacterium acnes* ATCC 11827 titrated at a concentration of  $2.6 \times 10^4$  cells per milliliter of medium.

The result is shown in Table 2.

10 Table 2

	<i>Propionibacterium acnes</i>	
	MIC ( $\mu\text{g/ml}$ )	MBC ( $\mu\text{g/ml}$ )
<i>Salix alba</i> extract	1560	3120
1,2-decanediol	620	1250
<i>Salix alba</i> extract +1,2-decanediol (1:1)	620	620
benzoyl peroxide	480	480

Minimum Inhibition Concentration (MIC) and Minimum Bactericide Concentration (MBC) of 1,2-Decanediol and *Salix alba* extract against *Propionibacterium acnes*

- 15 *Salix alba* extract alone shows only poor antibacterial activity.

1,2-decanediol is known to be effective against *P. acnes*.

The combination (1:1) of *Salix alba* extract and 1,2-decanediol surprisingly displayed a synergistic antibacterial effect against *P. acnes*.

- 20 A combination of 1,2-decanediol and *Salix alba* extract is capable to obtain the same MIC of the double concentration of 1,2-decanediol and to improve dramatically its MBC.

The selected order degree of the association is in line with benzoyl peroxide that is commonly known as strong antibacterial agent against *P. acnes*.

### ***In vitro* evaluation of the anti-inflammatory activity of *Salix alba* extract and 1,2-decanediol**

The aim of the test was the evaluation of the anti-inflammatory activity of *Salix alba* extract, 1,2-decanediol and their combination by means of the study of TNFalpha, IL1alpha, IL8 synthesis modulation in a biological experimental model (keratinocyte cell culture HaCat).

TNFalpha, IL1alpha, IL8 are inflammatory mediators related to the acneic process.

Keratinocyte cell culture were selected as experimental model on the base that the acneic process is performed inside the sebaceous glands follicle, a tissue composed by keratinocytes.

In order to stimulate the inflammatory process in our experimental model, lipopolysaccharides (LPS) were selected. LPS are pro-inflammatory mediators secreted by bacteria, e.g. by *P. acnes*.

1,2-decanediol (SMAL) was emulsified with corn oil (37°C) in mechanical agitation and addition of culture medium, starting from the following ratio: 0.05 g emulsified with 100 µl corn oil in a final volume of culture medium of 1 ml (37°C).

*Salix alba* extract (WMAL) was direct diluted in culture medium, starting from the following ratio: 0.05 g in 1 ml (37°C); subsequent dilutions in culture medium (37°C).

For the test execution, human keratinocytes (HaCat) were treated with LPS (Lipopolysaccharide from *Escherichia coli*, 10 ng/ml) and with tested product at 3 concentrations, chosen among non-cytotoxic ones after a preliminary cytotoxicity test.

At the end of the monitored experimental period, cytokine levels were measured by means of ELISA assay.

Results were compared to negative control (cells not subjected to LPS, CTR-) and positive control (cells treated with LPS, CTR+).

A preliminary cytotoxicity test was performed on the two products by using a concentration range from 5.0% to 0.0012% (serial dilution 1:2). According to obtained results, the following concentrations were chosen for the analysis of the anti-inflammatory activity:

1,2-decanediol (SMAL): 0.002%

*Salix alba* extract (WMAL): 0.04% - 0.02% - 0.01%



A second cytotoxicity test was performed on the mix of the two raw materials preliminary to the beginning of the test to verify the action synergism in the antinflammatory activity; tested concentrations were the following:

- 5 SMAL 0.002% + WMAL: 0.04% - 0.02% - 0.01%

Culture media of controls and cells treated with tested product were used for the dosage of pro-inflammatory cytokines TNFalpha, IL1alpha and IL8 by means of ELISA method.

Commercial ELISA kits were used for the determination of cytokine quantity.

- 10 The quantitative determination uses a calibration curve made-up of standard known and growing concentrations of standard cytokine.

The data obtained in the different experimental groups were subjected to statistical analysis and compared according to t-test. The variations are considered significant for  $p < 0.05$ .

15

In table 3 below the data obtained for each tested series are reported.

The results are expressed as cytokine released into the medium during the experimental period (mean value  $\pm$  dev.st.) and as mean % variation compared to the controls.

- 20 In order to compare the two different work sessions, the obtained data were normalized in a 0 – 100% scale, in which CTR- is 0 and CTR+ is 100%; all the other data were calculated in this interval.

On these data, statistical analysis by t-test was performed and variations are considered significant for  $p < 0.05$ .

- 25 On the base of the results obtained, it is observed that SMAL and WMAL are able to significantly reduce the LPS-induced release of the inflammation markers TNFalpha, IL1alpha and IL8, which are all related to acne.

For all substances analyzed, the substances WMAL and SMAL in combination show a synergistic effect.

30

Table 3

TNF-ALPHA	Normalized data 0-100%				
		dev std	T-test vs CTR+	T-test vs CTR+ +WMAL	T-test vs CTR+ +SMAL
CTR-	0				
CTR+	100.00%	6.2%			
WMAL 0,4%	32.94%	22.2%	0.0545		
SMAL 0,02%	18.45%	3.9%	0.0040		
WMAL 0,4%+SMAL 0,02%	-25.00%	8.5%	0.0042	0.0751	0.0224

IL-8	Normalized data 0-100%				
		dev std	T-test vs CTR+	T-test vs CTR+ +WMAL	T-test vs CTR+ +SMAL
CTR-	0				
CTR+	100.00%	9.4%			
WMAL 0,4%	17.77%	0.4%	0.0064		
SMAL 0,02%	34.56%	0.3%	0.0101		
WMAL 0,4%+SMAL 0,02%	-13.76%	2.9%	0.0011	0.0044	0.0019

IL-6	Normalized data 0-100%				
		dev std	T-test vs CTR+	T-test vs CTR+ +WMAL	T-test vs CTR+ +SMAL
CTR-	0				
CTR+	100.00%	45.6%			
WMAL 0,4%	75.81%	111.8%	0.8035		
SMAL 0,02%	61.69%	106.6%	0.6864		
WMAL 0,4%+SMAL 0,02%	-21.43%	7.2%	0.0017	0.3444	0.3861

5

Dosage of cytokine in cell culture CTR-, CTR+, treated with SMAL, WMAL and their associations. The results are expressed as mean value  $\pm$  dev.st. (expressed in ng/L) and as mean % variation compared to the controls.

- 10 Formulations can be of various nature both water-based, hydro-alcohol and anhydrous. Among the most commonly used include: surfactants systems ( including even such as shampoo , bubble bath, shower gel, liquid soaps and solid soaps, micellar waters, liquid detergents), water -in-oil emulsions, oil-in-water emulsions, serums, gels, oils, aqueous

solutions, hydroalcoholic solutions, anhydrous sticks, compact founding powders, lotions, milks, suncreams, after sun products and camouflage products (i.e. CC creams, BB creams).

It is optionally possible and advantageous to use the compositions according to the invention as a base for pharmaceutical formulations.

5

It is of course known to the person skilled in the art that cosmetic compositions are usually inconceivable without the customary auxiliaries and additives. Among these are included, for example, consistency-imparting agents, fillers, perfume, colorants, emulsifiers, additional active compounds such as vitamins or proteins, sunscreens, stabilisers, insect repellents, alcohol, water, salts, substances having proteolytic or keratolytic activity, thickeners, emollients, fatty acids, chelating agents, soothing agents, glycols, colorants, buffering substances.

The willow bark extract is prepared according to the Ph.Eur. monograph "Extracta". Whole or fragmented dried bark of young branches or whole dried pieces of current year twigs of various species of genus *Salix* including *S. purpurea* L., *S. saphnoides* Vill. And *S. fragilis* L. are extracted with water and/or ethanol. The total content of salicylic derivatives expressed in salicin has to be at least 5%; preferably between 10 and 20%.

The *Salix alba* extract according to the present invention has to be titrated to a total concentration of salicylic derivatives expressed as salicin not less than 20 % (w/w).

The ratio between *Salix alba* extract and 1,2-decanediol is between 1:100 and 100:1, or between 1:50 and 50:1, or between 1:10 and 10:1, preferably 1:5 and 5:1; more preferably 1:1.

The overall amount of *Salix alba* extract in the formula is in a range between 0.001% and 10%, preferably between 0.01 % (w/w) and 5 % (w/w), more preferably between 0.3 % (w/w) and 1 % (w/w).

The overall amount of 1,2-decanediol in the formula is in a range between 0.001 % (w/w) and 10 % (w/w), preferably between 0.01 % (w/w) and 5 % (w/w), more preferably between 0.3 % (w/w) and 1 % (w/w).

**Examples**

The following examples shall not represent a restriction of the invention.

**Example 1**

## 5 Suncream

INCI NAME	% (w/w)
Avobenzone	0-5
Glycerol	0-5,00
Panthenol	0-1,00
Disodium EDTA	0,10
Glyceryl Stearate, PEG-100 Stearate (50%:50%) (Arlacel 165V P)	1-5,00
4-Methylbenzylidene Camphor	1-4,00
Citrus Aurantius Amara	0-1
Xanthan Gum	0-1
Ascorbyl Tetraisopalmitate	0,20
Polyacrylamide (45%), C13-14 Isoparaffin (25%), Laureth-7 (8%), Aqua (22%) (Sepigel 305)	0-2,00
Methylene Bis-Benzotriazolyl Tetramethylbutylphenol, Aqua, Decyl Glucoside, Propylene Glycol, Xanthan Gum (Tinosorb A2B)	0-2,00
Ethylhexyl Methoxycinnamate	0-8,00
Niacinamide	0-1
Magnesium Aluminum Silicate	0-0,50
Dicaprylyl Carbonate	1-5,00
1,2-Hexanediol, Caprylyl Glycol (50%:50%) (Symdiol 68)	0,50
Soy Isoflavones	0,30
Ethylhexyl Triazone	0-2,00
Titanium Dioxide (75%), Silica (10%), Dimethicone (15%) (Parsol TX)	0-5
1,2-Decanediol	0,30
<i>Salix alba</i> (Willow) Bark Extract	0,30
Tocopheryl Acetate	0,50
Butylated hydroxytoluene	0-0,05
Hydroxyacetophenone	0-0,50
Demin. H <sub>2</sub> O	ad 100,00

Example 2

## Serum

INCI NAME	% (w/w)
Sodium Hydroxide	0-8
Glycolic Acid	0-20,00
Lactic Acid	0-3
Niacinamide	1,00
Caprylyl Glycol	0-5,00
Xanthan Gum	0,10
Polyacrylate Crosspolymer-6	2,20
Dicaprylyl Ether	0-4,00
Salicylic Acid	0-2
1,2-Decanediol	1,00
Polyglyceryl-6 Stearate (85-98%), Polyglyceryl-6 Behenate (2-15%) (Tego Care PBS 6)	0-4
<i>Salix alba</i> (Willow) Bark Extract	0,30
Aluminum Starch Octenylsuccinate	0-2,00
Dipotassium Glycirrhizinate	0-2
Sodium Phytate, Aqua, Alcohol	0,10
Demin. H <sub>2</sub> O	ad 100,00

Example 3

## Hydrating Cream

INCI NAME	% (w/w)
Disodium EDTA	0,10
Glycerol	0-7,00
Sodium Hyaluronate	0-1
Niacinamide	1,00
Caprylyl Glycol	0-2,00
Xanthan Gum	0,10
Polyacrylate Crosspolymer-6	0-3,00
Dicaprylyl Ether	0-5,00
1,2-Decanediol	0,30
Polyglyceryl-6 Stearate (85-98%), Polyglyceryl-6 Behenate (2-15%) (Tego Care PBS 6)	2,50
<i>Salix alba</i> (Willow) Bark Extract	0,3
Lactic Acid	0-1
Sodium Phytate (48-52%), Aqua (48-52%), Alcohol(1%) (Dermosoft PA 3)	0,05
Demin. H <sub>2</sub> O	ad 100,00

Example 4

## Gel

INCI NAME	% (w/w)
Disodium EDTA	0,10
Glycerol	0-3,00
Niacinamide	1,00
Caprylyl Glycol	0-2,00
Xanthan Gum	0,20
Polyacrylate Crosspolymer-6	0-3,0
1,2-Decanediol	0,50
<i>Salix alba</i> (Willow) Bark Extract	0,50
Lactic Acid	0,50
Sodium Phytate (48-52%), Aqua (48-52%), Alcohol(1%) (Dermosoft PA 3)	0,10
Demin. H <sub>2</sub> O	ad 100,00

Example 5

Liquid detergent

INCI NAME	% (w/w)
Disodium EDTA	0,10
Glycerol	0-4,00
Hydroxypropyl Guar Hydroxypropyltrimonium Chloride (Jaguar C162)	0-1,0
Niacinamide	0,30
Methylpropanediol (80%), Caprylyl Glycol (15%), Phenylpropanol (5%) (Dermosoft OMP)	0-5,0
Xanthan Gum	0,30
Sodium Cocoamphoacetate	0-10,0
Disodium Laureth Sulfosuccinate	0-10,0
1,2-Decanediol	1,00
PEG-40 Hydrogenated Castor Oil	1,00
<i>Salix alba</i> (Willow) Bark Extract	0,01
Lactic Acid	1,00
Demin. H <sub>2</sub> O	ad 100,00

Example 6

## CC Cream

INCI NAME	% (w/w)
Aqua	56,00
Glycerol	2,00
Niacinamide	0,50
<i>Salix alba</i> (Willow) Bark Extract	0,50
Magnesium Sulfate Heptahydrate	0,50
Methylpropanediol (80%), Caprylyl Glycol (15%), Phenylpropanol (5%) (Dermosoft OMP)	2,00
Cetyl Dimethicone	2,00
Octyldodecanol	10,00
Ethylhexyl Palmitate	8,00
Dimethicone	1,50
Hydrogenated Castor Oil	1,50
1,2-Decanediol	1,00
Cetyl PEG PPG-10/1 Dimethicone (Abil EM 90)	2,50
Titanium dioxide	5,00
Tocopheryl Acetate	1,00
Mica (48-59%), Titanium Dioxide (41-52%) (Timica Terra White)	4,00
Mica (44-54%), Iron Oxides (36-50%), Titanium Dioxide (2-8%) (Timica Terra Brown)	2,00
Demin. H <sub>2</sub> O	ad 100,00



Example 7

Moisturizing cream

INCI NAME	% (w/w)
Disodium EDTA	0 - 0,10
Glycerin	0 - 6,00
Niacinamide	0 - 1,00
Sodium Phytate	0 - 0,05
Sodium Hyaluronate	0,2 - 0,9
<i>Salix alba</i> (Willow) Bark Extract	0,01 - 0,3
Caprylyl Glycol	0,5 - 1,5
Xanthan Gum	0 - 0,30
Polyacrilate Cossopolymer-6	0 - 1,50
Dicaprylyl Ether	1 - 5,00
1,2-Decanediol	0 - 0,9
Polyglyceryl-6 Stearate (85-98%), Polyglyceryl-6 Behenate (2-15%) (Tego Care PBS 6)	2,50
Aluminum Starch Octenylsuccinate	0-2,00
Lactic Acid	0-0,15
Demin. H <sub>2</sub> O	ad 100

Example 8

5 Detergent

INCI NAME	% (w/w)
Glycerol	0,1-2,00
Disodium EDTA	0-0,10
Niacinamide	0,1-0,90
Phytospingosine HCl	0,01-0,1
1,2-Decanediol	0,01-3
<i>Salix alba</i> (Willow) Bark Extract	0,01-0,9
PEG-40 Hydrogenated Castor Oil	0-1,00
Polyquaternium-10	0-1
Sodium Cocoamphoacetate	1-6,00
Disodium Laureth Sulfosuccinate	1-8,00
Methylpropanediol (80%) , Caprylyl Glycol (15%), Phenylpropanol (5%) (Dermosoft OMP)	1-2,50
Lactic Acid	0,01-0,90
Demin. H <sub>2</sub> O	ad 100,00

Example 9

## Suncream

INCI NAME	% (w/w)
Avobenzene	0-5
Glycerol	0-5,00
Panthenol	0-1,00
Disodium EDTA	0,10
Glyceryl Stearate, PEG-100 Stearate (50%:50%) (Arlacel 165V P)	1-5,00
4-Methylbenzylidene Camphor	1-4,00
Citrus Aurantius Amara	0-1
Xanthan Gum	0-1
Ascorbyl Tetraisopalmitate	0,20
Polyacrylamide (45%), C13-14 Isoparaffin (25%), Laureth-7 (8%), Aqua (22%) (Sepigel 305)	0-2,00
Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (46-55%), Aqua (33,9-47,7%), Decyl Glucoside (6-10%), Propylene Glycol 0,2-0,6%), Xanthan Gum (0,1-0,5%) (Tinosorb M)	0-10,00
Ethylhexyl Methoxycinnamate	0-8,00
Niacinamide	0-1
Magnesium Aluminum Silicate	0-0,50
Dicaprylyl Carbonate	1-5,00
1,2-Hexanediol (and) Caprylyl Glycol (50%:50%) (Symdiol 68)	0,50
Soy Isoflavones	0,30
Ethylhexyl Triazone	0-2,00
Titanium Dioxide (75%), Silica (10%), Dimethicone (15%) (Parsol TX)	0-5
1,2-Decanediol	0,30
<i>Salix alba</i> (Willow) Bark Extract	0,30
Tocopheryl Acetate	0,50
Butylated hydroxytoluene	0-0,05
Hydroxyacetophenone	0-0,50
Demin. H <sub>2</sub> O	ad 100,00

Example 10

## Suncream 2

INCI NAME	% (w/w)
Avobenzone	0-5
Glycerol	0-5,00
Panthenol	0-1,00
Disodium EDTA	0,10
Glyceryl Stearate, PEG-100 Stearate (50%:50%) (Arlacel 165V P)	1-5,00
4-Methylbenzylidene Camphor	1-4,00
Citrus Aurantius Amara	0-1
Xanthan Gum	0-1
Ascorbyl Tetraisopalmitate	0,20
Polyacrylamide (45%), C13-14 Isoparaffin (25%), Laureth-7 (8%), Aqua (22%) (Sepigel 305)	0-2,00
Aqua (37-46%), Tris-Biphenyl Triazine (47-53%), decyl glucoside (6,5-8,5%), disodium phosphate (0.2%-0.6%), butylene glycol (0.2%-0.6%), xanthan gum (0.1%-0.3%) (Tinosorb A2B)	0-10,00
Ethylhexyl Methoxycinnamate	0-8,00
Niacinamide	0-1
Magnesium Aluminum Silicate	0-0,50
Dicaprylyl Carbonate	1-5,00
1,2-Hexanediol (and) Caprylyl Glycol (50%:50%) (Symdiol 68)	0,50
Soy Isoflavones	0,30
Ethylhexyl Triazone	0-2,00
Titanium Dioxide (75%), Silica (10%), Dimethicone (15%) (Parsol TX)	0-5
1,2-Decanediol	0,30
<i>Salix alba</i> (Willow) Bark Extract	0,30
Tocopheryl Acetate	0,50
Butylated hydroxytoluene	0-0,05
Hydroxyacetophenone	0-0,50
Demin. H <sub>2</sub> O	ad 100,00

## Claims

1. Cosmetic or dermatological composition for use in the antibacterial and/or anti-inflammatory treatment of acne comprising 1, 2-decanediol and *Salix alba* extract.
2. Composition for use according to claim 1, characterized in that the proportion of 1, 2-decanediol is in the range between 0.001 % (w/w) and 10 % (w/w), In particular in the range between 0.01 % (w/w) and 5% (w/w), based on the total mass of the preparation.
3. Composition for use according to one of the preceding claims, characterized in that the proportion of *Salix alba* extract is in the range between 0.001 % (w/w) and 10 % (w/w), preferably between 0.01 % (w/w) and 5 % (w/w), based on the total mass of the preparation.
4. Composition for use according to one of the preceding claims, characterized in that the ratio between *Salix alba* extract and 1,2-Decanediol is between 1:10 and 10:1; preferably between 1:5 and 5:1, more preferably 1:1.
5. Composition for use according to one of the preceding claims in the form of a surfactant system, water-in-oil emulsion, oil-in-water emulsion, serum, gel, oil, aqueous solution, hydroalcoholic solution, anhydrous sticks, compact founding powder, lotion, milk, suncream, after sun product or camouflage product.
6. Composition for use according to one of the preceding claims additionally comprising customary auxiliaries and additives.
7. Composition for use according to any of claims 1 to 6, characterized that it is a suncream comprising 0.3% (w/w) *Salix alba* extract, 0.3% (w/w) 1, 2-decanediol, up to 10% (w/w) of a mixture of Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (46-55%)/Aqua (33,9-47,7%)/Decyl Glucoside (6-10%)/Propylene Glycol 0,2-0,6%)/Xanthan Gum (0,1-0,5%), up to 0.5% (w/w) Magnesium Aluminum Silicate, up to 5% (w/w) of a mixture of Titanium Dioxide (75%)/Silica (10%)/Dimethicone (15%), up to 8% (w/w) Ethylhexyl Methoxycinnamate, up to 5% (w/w) Dicaprylyl Carbonate, up to 5% (w/w) Avobenzonone, up to 2% (w/w) Ethylhexyl Triazone.
8. Composition for use according to any of claims 1 to 6, characterized that it is a suncream comprising 0.3% (w/w) *Salix alba* extract, 0.3% (w/w) 1, 2-decanediol, up to 10% (w/w) of a mixture of Aqua (37-46%)/Tris-Biphenyl Triazine (47-53%)/decyl glucoside (6,5-8,5%)/disodium phosphate (0.2%-0.6%)/butylene glycol (0.2%-0.6%)/xanthan gum (0.1%-0.3%), up to 0.5% (w/w) Magnesium Aluminum Silicate, up to 5% (w/w) of a mixture of Titanium Dioxide (75%)/Silica (10%)/Dimethicone (15%)/up to 8% (w/w) Ethylhexyl Methoxycinnamate, up to 5% (w/w) Dicaprylyl Carbonate, up to 5% (w/w) Avobenzonone, up to 2% (w/w) Ethylhexyl Triazone.

9. Composition for use according to any of claims 1 to 6, characterized that it is a detergent comprising 0.01 to 0.9% (w/w) *Salix alba* extract, 0.01 to 3% (w/w) 1, 2-decanediol, 0.01 to 0.1% (w/w) phytosphingosine HCl, up to 6% (w/w) sodium cocoamphoacetate, up to 8% (w/w) disodiumlaureth sulfosuccinate, up to 1% (w/w) polyquaternium-10.
10. Composition for use according to any of claims 1 to 6, characterized that it is a moisturizing cream comprising 0.01 to 0.3% (w/w) *Salix alba* extract, up to 0.9% (w/w) 1, 2-decanediol, 0.2 to 0.9% (w/w) sodium hyaluronate, 1 to 5% (w/w) dicaprylyl ether, up to 2% (w/w) aluminium starch octenylsuccinate, up to 0.5% (w/w) sodium phytate.
11. Composition for use according to any of claims 1 to 6, characterized that it is a CC cream comprising 0.5% (w/w) *Salix alba* extract, 1% (w/w) 1, 2-decanediol, up to 2% (w/w) of a mixture of Methylpropanediol (80%)/Caprylyl Glycol (15%)/Phenylpropanol (5%), up to 5% (w/w) titanium dioxide, up to 2% (w/w) of a mixture of Mica (44-54%)/Iron Oxides (36-50%)/Titanium Dioxide (2-8%), up to 0.5% (w/w) magnesium sulfate heptahydrate.
12. Composition for use according to any of claims 1 to 6, characterized that it is a liquid detergent comprising 0.01% (w/w) *Salix alba* extract, 1% (w/w) 1, 2-decanediol, up to 1% (w/w) of hydroxypropyl guar hydroxypropyltrimonium chloride, up to 10% (w/w) sodium cocoamphoacetate, up to 5% of a mixture of Methylpropanediol (80%)/Caprylyl Glycol (15%)/Phenylpropanol (5%).
13. Composition for use according to any of claims 1 to 6, characterized that it is a gel comprising 0.5% (w/w) *Salix alba* extract, 0.5% (w/w) 1, 2-decanediol, up to 2% (w/w) caprylyl glycol, up to 3% (w/w) polyacrylate crosspolymer-6, up to 1% (w/w) niacinamide.
14. Composition for use according to any of claims 1 to 6, characterized that it is a serum comprising 0.3% (w/w) *Salix alba* extract, 1% (w/w) 1, 2-decanediol, up to 4% (w/w) of a mixture of Polyglyceryl-6 Stearate (85-98%)/Polyglyceryl-6 Behenate (2-15%), up to 5% (w/w) caprylyl glycol, up to 2% (w/w) salicylic acid, up to 2% (w/w) aluminium starch octenylsuccinate, up to 2% (w/w) dipotassium glycirrhizinate.

**INTERNATIONAL SEARCH REPORT**

International application No  
PCT/EP2016/000312

**A. CLASSIFICATION OF SUBJECT MATTER**  
 INV. A61Q19/00 A61K8/34 A61K8/365 A61K8/97 A61K36/76  
 A61K8/60  
 ADD.  
 According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
 Minimum documentation searched (classification system followed by classification symbols)  
 A61Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EPO-Internal, WPI Data, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE GNPD [Online] MINTEL; 1 December 2010 (2010-12-01), Boscia: "Clear Complexion Moisturizer with Botanical Blast", XP002743241, Database accession no. 1448967	1-3,5,6
Y	product description; ingredients -----	1-14
X	DE 103 41 179 A1 (BEIERSDORF AG [DE]) 31 March 2005 (2005-03-31)	1-6
Y	claims page 2, paragraph 7 pages 16-17; example 10 foundation; pages 17-18; example 3 -----	1-14
	-/--	

Further documents are listed in the continuation of Box C.  See patent family annex.

\* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>
---	---

Date of the actual completion of the international search <b>6 April 2016</b>	Date of mailing of the international search report <b>15/04/2016</b>
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <b>Grillenberger, Sonja</b>
--	---

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2016/000312

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/172847 A1 (MODAK SHANTA [US] ET AL) 8 July 2010 (2010-07-08)	1-6
Y	claims page 1, paragraph 3 cream 5; page 16; table 43	1-14
X	----- WO 2008/046791 A1 (SYMRISE GMBH & CO KG [DE]; SCHMAUS GERHARD [DE]; LANGE SABINE [DE]; RO) 24 April 2008 (2008-04-24)	1-6
Y	claim 2 page 4, lines 4-8 pages 1-3	1-14
Y	----- DATABASE GNPD [Online] MINTEL; 1 November 2011 (2011-11-01), Kate Somerville: "Acne 24 Hour Pimple Punisher", XP002743242, Database accession no. 1676345 product description; ingredients	1-14
Y	----- DE 10 2012 223401 A1 (HENKEL AG & CO KGAA [DE]) 18 June 2014 (2014-06-18) claims 1,4 page 5, paragraph 20	1-14
T	----- NN: "Salicylic acid", en.wikipedia.org, 26 July 2015 (2015-07-26), pages 1-9, XP002743243, Retrieved from the Internet: URL: <a href="https://en.wikipedia.org/wiki/Salicylic_acid">https://en.wikipedia.org/wiki/Salicylic acid</a> [retrieved on 2015-08-12] introduction; history; dietary sources; medicinal and cosmetic uses	1-14
	-----	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2016/000312

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 10341179	A1	31-03-2005	AT 532508 T 15-11-2011
			DE 10341179 A1 31-03-2005
			EP 1598064 A1 23-11-2005
-----			
US 2010172847	A1	08-07-2010	US 2010172847 A1 08-07-2010
			WO 2010091415 A1 12-08-2010
-----			
WO 2008046791	A1	24-04-2008	EP 1915982 A1 30-04-2008
			EP 2063856 A1 03-06-2009
			US 2010324152 A1 23-12-2010
			WO 2008046791 A1 24-04-2008
-----			
DE 102012223401	A1	18-06-2014	DE 102012223401 A1 18-06-2014
			EP 2742928 A1 18-06-2014
-----			